Quick Listen: Scrip's Five Must-Know Things
Executive Summary
In this week's podcast edition of Five Must-Know Things: a look ahead at potential oncology blockbuster approvals; strong data for Mirati’s KRAS contender in colorectal cancer; Keytruda’s architect reflects in its great success; Amgen’s waiting game for ChemoCentryx; and a look at dynamics in China’s sizzling immuno-oncology market.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 9 September 2022, including: a look ahead at potential oncology blockbuster approvals; strong data for Mirati Therapeutics, Inc.’s KRAS contender in colorectal cancer; Keytruda’s architect reflects in its great success; Amgen, Inc.’s waiting game for ChemoCentryx, Inc.; and a look at dynamics in China’s sizzling immuno-oncology market.
This and all our other podcasts are available on the Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "Five Potential Blockbuster Oncology Approvals To Look Out For In 2023" - Scrip, 6 Sep, 2022.)
(Also see "ESMO: Mirati’s Adagrasib Appears To Maintain CRC Edge In KRAS Race" - Scrip, 7 Sep, 2022.)
(Also see "Architect Of Keytruda Reflects On A Great Scientific Success Story" - Scrip, 5 Sep, 2022.)
(Also see "Amgen Played Waiting Game Before Agreeing $3.7bn ChemoCentryx Deal" - Scrip, 2 Sep, 2022.)
(Also see "H1 Winners And Laggards In China's Sizzling Home-Grown IO market" - Scrip, 8 Sep, 2022.)